Perhaps timely catching Diebold Nixdorf Incorporated (DBD) would be a good idea

Diebold Nixdorf Incorporated (NYSE: DBD) stock jumped 5.24% on Friday to $2.21 against a previous-day closing price of $2.10. With 0.87 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.92 million shares. During the session, the Software – Application company that operates in wider Technology sector, reached to the highest price of $2.2300 whereas the lowest price it dropped to was $2.0650. The 52-week range on DBD shows that it touched its highest point at $10.27 and its lowest point at $1.26 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 2.99.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DBD was up-trending over the past week, with a rise of 22.78%, but this was up by 52.41% over a month. Three-month performance dropped to -17.54% while six-month performance fell -36.49%. The stock lost -77.65% in the past year, while it has gained 55.63% so far this year. A look at the trailing 12-month EPS for DBD yields -5.96 with Next year EPS estimates of 1.47. For the next quarter, that number is 0.38. This implies an EPS growth rate of 71.00% for this year and 253.10% for next year. EPS is expected to grow by 3.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 17.00%.

Float and Shares Shorts:

At present, 79.10 million DBD shares are outstanding with a float of 71.41 million shares on hand for trading. On Oct 13, 2022, short shares totaled 7.4 million, which was 9.36% higher than short shares on Sep 14, 2022. In addition to Mr. Jeffrey L. Rutherford as the firm’s Exec. VP & CFO, Mr. Olaf Heyden serves as its Exec. VP & COO.


Institutional Ownership:

Through their ownership of 83.98% of DBD’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.05% of DBD, in contrast to 55.77% held by mutual funds. Shares owned by individuals account for 23.34%. As the largest shareholder in DBD with 13.34% of the stake, BlackRock Fund Advisors holds 10,546,735 shares worth 10,546,735. A second-largest stockholder of DBD, The Vanguard Group, Inc., holds 5,698,271 shares, controlling over 7.21% of the firm’s shares. Millennium Management LLC is the third largest shareholder in DBD, holding 3,978,670 shares or 5.03% stake. With a 3.19% stake in DBD, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 2,523,583 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.05% of DBD stock, is the second-largest Mutual Fund holder. It holds 1,617,149 shares valued at 15.03 million. 1290 VT GAMCO Small Company Value holds 1.76% of the stake in DBD, owning 1,390,000 shares worth 12.92 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DBD since 5 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DBD analysts setting a high price target of $5.00 and a low target of $3.00, the average target price over the next 12 months is $4.00. Based on these targets, DBD could surge 126.24% to reach the target high and rise by 35.75% to reach the target low. Reaching the average price target will result in a growth of 81.0% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. DBD will report FY 2022 earnings on 02/13/2024. Analysts have provided yearly estimates in a range of -$0.87 being high and -$1.04 being low. For DBD, this leads to a yearly average estimate of -$0.96. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Diebold Nixdorf Incorporated surprised analysts by -$0.35 when it reported -$0.11 EPS against a consensus estimate of $0.24. The surprise factor in the prior quarter was $0.52. Based on analyst estimates, the high estimate for the next quarter is $0.48 and the low estimate is $0.31. The average estimate for the next quarter is thus $0.39.

Summary of Insider Activity:

Insiders traded DBD stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 60 while that of sell transactions has risen to 25 over the past year. The total number of shares bought during that period was 1,990,785 while 312,863 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *